CA3226199A1 - Fibroblast-containing pharmaceutical composition for treating kidney disease - Google Patents

Fibroblast-containing pharmaceutical composition for treating kidney disease Download PDF

Info

Publication number
CA3226199A1
CA3226199A1 CA3226199A CA3226199A CA3226199A1 CA 3226199 A1 CA3226199 A1 CA 3226199A1 CA 3226199 A CA3226199 A CA 3226199A CA 3226199 A CA3226199 A CA 3226199A CA 3226199 A1 CA3226199 A1 CA 3226199A1
Authority
CA
Canada
Prior art keywords
fibroblasts
less
pharmaceutical composition
kidney disease
vcam1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3226199A
Other languages
English (en)
French (fr)
Inventor
Takahiro IWAMIYA
Jun HOMMA
Tomomi Imamura
Yuimi MATSUOKA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metcela Inc
Original Assignee
Metcela Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metcela Inc filed Critical Metcela Inc
Publication of CA3226199A1 publication Critical patent/CA3226199A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3226199A 2021-09-08 2022-08-23 Fibroblast-containing pharmaceutical composition for treating kidney disease Pending CA3226199A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021146130 2021-09-08
JP2021-146130 2021-09-08
PCT/JP2022/031721 WO2023037868A1 (ja) 2021-09-08 2022-08-23 線維芽細胞を含む腎疾患治療用医薬組成物

Publications (1)

Publication Number Publication Date
CA3226199A1 true CA3226199A1 (en) 2023-03-16

Family

ID=85506601

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3226199A Pending CA3226199A1 (en) 2021-09-08 2022-08-23 Fibroblast-containing pharmaceutical composition for treating kidney disease

Country Status (7)

Country Link
US (1) US20240316113A1 (https=)
EP (1) EP4349349A4 (https=)
JP (1) JPWO2023037868A1 (https=)
CN (1) CN117750964A (https=)
AU (1) AU2022344667A1 (https=)
CA (1) CA3226199A1 (https=)
WO (1) WO2023037868A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3211113A1 (en) * 2021-03-04 2022-09-09 Metcela Inc. Lymphangiogenesis promoting factor-expressing fibroblast, and pharmaceutical composition containing same
CN119685401A (zh) * 2024-06-03 2025-03-25 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种改造成纤维细胞的方法及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102407387B1 (ko) * 2017-02-24 2022-06-10 가부시키가이샤 메토세라 섬유아세포를 포함하고, 심장 질환들의 치료를 위하여 사용될 수 있는 주사용 조성물, 및 치료 용도를 위하여 섬유아세포를 생산하는 방법
CA3110831A1 (en) 2018-08-29 2020-03-05 Metcela Inc. Method for producing fibroblast, and g-csf-positive fibroblast mass
WO2021133790A1 (en) * 2019-12-26 2021-07-01 Figene, Llc Prevention and treatment of kidney failure by administration of fibroblasts and products thereof
CN115210361B (zh) * 2020-03-04 2024-12-10 淋巴奥格尼克斯有限公司 促红细胞生成素产生能力增强的成纤维细胞、制造方法以及医药组合物
CA3211113A1 (en) * 2021-03-04 2022-09-09 Metcela Inc. Lymphangiogenesis promoting factor-expressing fibroblast, and pharmaceutical composition containing same

Also Published As

Publication number Publication date
CN117750964A (zh) 2024-03-22
JPWO2023037868A1 (https=) 2023-03-16
AU2022344667A1 (en) 2024-01-25
WO2023037868A1 (ja) 2023-03-16
EP4349349A4 (en) 2025-05-21
EP4349349A1 (en) 2024-04-10
US20240316113A1 (en) 2024-09-26

Similar Documents

Publication Publication Date Title
JP5240715B2 (ja) 脂肪組織由来多分化能幹細胞を含有する細胞製剤
JP6129418B2 (ja) ヒト胚性幹細胞から由来した間葉系幹細胞を有効成分として含有する肝繊維化または肝硬変予防及び治療用組成物
CN103340904A (zh) 治疗骨关节炎的组合物
CN113574167B (zh) 利用混合物4f增加干细胞生物学活性的组合物
CA3226199A1 (en) Fibroblast-containing pharmaceutical composition for treating kidney disease
Zhang et al. Combining injectable plasma scaffold with mesenchymal stem/stromal cells for repairing infarct cavity after ischemic stroke
JP6235795B2 (ja) 細胞のリプログラミングのための組成物
KR102104120B1 (ko) 사람 코 하비갑개 유래 중간엽 줄기세포 기반 3d 바이오프린팅 조직체 및 이의 이용
KR102152659B1 (ko) 편도 유래 중간엽 줄기세포의 조정 배지를 포함하는 암 전이 억제용 조성물
JP2023053044A (ja) エリスロポエチン産生能が亢進された線維芽細胞
KR102096886B1 (ko) 편도 유래 중간엽 줄기세포의 조정 배지를 포함하는 이식편대숙주 질환 예방 혹은 치료용 조성물
KR20200132550A (ko) 편도 유래 중간엽 줄기세포 또는 이의 조정 배지를 포함하는 혈관질환 예방 또는 치료용 조성물
JP7555142B2 (ja) 糖尿病を治療するための幹細胞薬
KR102526447B1 (ko) 편도 유래 중간엽 줄기세포의 조정 배지를 포함하는 간질환 예방 또는 치료용 조성물
KR101789475B1 (ko) 편도 유래 중간엽 줄기세포 또는 이의 조정 배지를 포함하는 골다공증 예방 또는 치료용 조성물
KR102037996B1 (ko) 편도 유래 중간엽 줄기세포 또는 이의 조정 배지를 포함하는 제2형 당뇨병 예방 또는 치료용 조성물
US20210196760A1 (en) Pharmaceutical composition for treating cartilage damage, comprising nasal septum chondrocytes
JP2023147910A (ja) 脊髄損傷治療剤
KR20170091882A (ko) 편도 유래 중간엽 줄기세포 또는 이의 조정 배지를 포함하는 골다공증 예방 또는 치료용 조성물
KR20240052103A (ko) 편도 유래 중간엽 줄기세포 제조 방법
KR20190122196A (ko) 편도 유래 중간엽 줄기세포 또는 이의 조정 배지를 포함하는 제2형 당뇨병 예방 또는 치료용 조성물
Hata www. pubstemcell. com
TW201034679A (en) Pharmaceutical composition for treating chronic renal disease
KR20160076225A (ko) 섬유아세포의 세포 증식 방법

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240105

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20241009

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250512

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250517

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250702

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20251103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260209